Every industry on earth is buzzing over the promise and potential of ChatGPT and similarly sharp AI models, whether “large language” or another generative form. Healthcare is no exception. But shouldn’t it be?

Buzzworthy developments of the past few days.

Fresh off its success using AI to develop a blockbuster COVID vaccine, up-and-coming biotech player Moderna (founded 2010) has won the confidence of 112-year-old Big Blue as a strategic partner.

Having identified an “urgent” need for guardrails to keep healthcare AI from veering into an avoidable ditch, the Coalition for Health AI has put together a 24-page guide applicable to numerous groups of stakeholders.

Bhvita Jani, research manager at the healthcare market analysis firm Signify Research, shares noteworthy happenings from the ECR expo floor.

ChatGPT isn’t capable of unilaterally guiding care for patients with cirrhosis or the liver cancer it tends to spawn, hepatocellular carcinoma (HCC). However, the large-language AI tool can competently assist clinicians.  

A popular marketer of handheld ultrasound devices has won FDA approval for an AI-enabled B-line quantification tool for use with patients suspected of having compromised lung function.

Radiology AI vendor Bot Image may market its prostate software not only for diagnosing cancer when suspected but also for performing prostate screenings.